Table 3.
Outcomes of the study population
| Pre-pandemic group(n = 32) | Pandemic group(n = 23) | Post-epidemic group(n = 39) | P* value | P** value | P*** value | |
|---|---|---|---|---|---|---|
| sICH, n (%) | 3(9.4) | 4(17.4) | 3(7.7) | 0.435 | 0.999 | 0.408 |
| Reperfusion mTICI 2b/3 | 25(78.1) | 17(73.9) | 36(92.3) | 0.717 | 0.168 | 0.066 |
| 90-day mRS ≤ 2, n (%) | 18(56.3) | 14(60.9) | 24(61.5) | 0.732 | 0.652 | 0.958 |
| 90-day mRS, median (IQR) | 2(0,4) | 2(1,5) | 2(1,4) | 0.650 | 0.612 | 0.894 |
| 90-day mortality, n (%) | 6(18.8) | 5(21.7) | 8(20.5) | 0.999 | 0.853 | 0.999 |
P* Pre-pandemic group vs. Pandemic group, P** Pre-pandemic group vs. Post-epidemic group,
P*** Pandemic group vs. Post-epidemic group,
NIHSS National Institutes of Health Stroke scale, sICH Symptomatic intracranial haemorrhage transformation, mTICI Modified Treatment in Cerebral Infarction, mRS Modified Rankin Scale, IQR Interquartile range (25%–75%)